Enzyme-Triggered Chemodynamic Therapy via a Peptide-H2S Donor Conjugate with Complexed Fe2+

Inducing high levels of reactive oxygen species (ROS) inside tumor cells is a cancer therapy method termed chemodynamic therapy (CDT). Relying on delivery of Fenton reaction promoters such as Fe²⁺, CDT takes advantage of overproduced ROS in the tumor microenvironment. We developed a peptide-H₂S donor conjugate, complexed with Fe²⁺, termed AAN - PTC – Fe²⁺ . The AAN tripeptide was specifically cleaved by legumain, an enzyme overexpressed in glioma cells, to release carbonyl sulfide (COS). Hydrolysis of COS by carbonic anhydrase formed H₂S, an inhibitor of catalase, an enzyme that detoxifies H₂O₂. Fe²⁺ and H₂S together increased intracellular ROS levels and decreased viability in C6 glioma cells compared with controls lacking either Fe²⁺, the AAN sequence, or the ability to generate H₂S. AAN - PTC – Fe²⁺ performed better than temezolimide while exhibiting no cytotoxicity toward H9C2 cardiomyocytes. This study provides an H₂S-amplified, enzyme-responsive platform for synergistic cancer treatment.